

WEST Search History

DATE: Friday, November 15, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB; PLUR=YES; OP=OR</i>			
L1	fendly.in.	12	L1

END OF SEARCH HISTORY

result in loss of user privileges and other penalties.
***** STN Columbus *****

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREIGN no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCELLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
STN Operating Hours Plus Help Desk Availability
NEWS HOURS General Internet Information
NEWS INTER Welcome Banner and News Items
NEWS LOGIN Direct Dial and Telecommunication Network Access to STN
NEWS PHONE CAS World Wide Web Site (General information)
NEWS WWW

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

FILE 'HOME' ENTERED AT 10:53:01 ON 05 NOV 2002

=> file medline, cancerlit, biosis, confsci, caplus, embase, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21

FILE 'MEDLINE' ENTERED AT 10:53:32 ON 05 NOV 2002

FILE 'CANCELLIT' ENTERED AT 10:53:32 ON 05 NOV 2002

FILE 'BIOSIS' ENTERED AT 10:53:32 ON 05 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CONFSCI' ENTERED AT 10:53:32 ON 05 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 10:53:32 ON 05 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:53:32 ON 05 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:53:32 ON 05 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

<-----User Break----->
<-----User Break----->
u

SEARCH ENDED BY USER

=> s her2 or erb2 or cerbb2 or pl85
L1 9309 HER2 OR ERB2 OR CERBB2 OR P185

=> s l1 and antibody?
L2 3941 L1 AND ANTIBOD?

=> s l2 and chemotherapeutic?
L3 503 L2 AND CHEMOTHERAPEUTIC?

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 418 DUP REM L3 (85 DUPLICATES REMOVED)

=> s l4 not py=>1996
'1996' NOT A VALID FIELD CODE
6 FILES SEARCHED....
L5 5 L4 NOT PY=>1996

=> d 1-5

L5 ANSWER 1 OF 5 MEDLINE
AN 91365853 MEDLINE
DN 91365853 PubMed ID: 1679763
TI Monoclonal antibody therapy of human cancer: taking the
HER2 protooncogene to the clinic.

AU Shepard H M; Lewis G D; Sarup J C; Fendly B M; Maneval D; Mordenti J;
 Figari I; Kotts C E; Palladino M A Jr; Ullrich A; +
 CS Department of Developmental Biology, Genentech, Inc., South San Francisco,
 California 94080.
 SO JOURNAL OF CLINICAL IMMUNOLOGY, (1991 May) 11 (3) 117-27. Ref: 35
 Journal code: 8102137. ISSN: 0271-9142.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199110
 ED Entered STN: 19911103
 Last Updated on STN: 20000303
 Entered Medline: 19911011
 L5 ANSWER 2 OF 5 CANCELRIT
 AN 95611685 CANCELRIT
 DN 95611685
 TI Monoclonal antibodies directed against growth factor receptors
 enhance the efficacy of chemotherapeutic agents (Meeting
 abstract).
 AU Baselga J; Fan Z; Norton L; Mendelsohn J
 CS Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
 SO Ann Oncol. (1994) 5 (Suppl 5) A010.
 ISSN: 0923-7534.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 199509
 ED Entered STN: 19950906
 Last Updated on STN: 19950906
 L5 ANSWER 3 OF 5 USPATFULL
 AN 95105868 USPATFULL
 TI Cell signaling inhibitors
 IN Michnick, John, Seattle, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Klein, J. Peter, Vashon Island, WA, United States
 Rice, Glenn C., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5470878 19951128
 AI US 1993-164081 19931208 (8)
 RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
 now abandoned
 DT Utility
 FS Granted
 INCL INCLM: 514/558.000
 INCL INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;
 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;
 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000;
 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;
 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;
 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/557.000;
 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
 NCL NCLM: 514/558.000
 NCLS: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;
 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000;
 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000;
 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000
 IC (6)
 ICM: A61K031-20
 ICS: C07C233-00

EXF 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198;
 564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552;
 514/523; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 4 OF 5 USPATFULL
 AN 9547701 USPATFULL
 TI Polymeric carriers for non-covalent drug conjugation
 IN Gustavson, Linda M., 19809 - 31st St., NE., Seattle, WA, United States
 98155
 Anderson, David C., 200 Lassen Dr., San Bruno, CA, United States 94066
 Morgan, Jr., Alton C., 803 Driftwood Pl., Edmonds, WA, United States
 98020
 PI US 5420105 19950530
 AI US 1993-95515 19930726 (8)
 RLI Continuation-in-part of Ser. No. US 1988-248456, filed on 23 Sep 1988,
 now patented. Pat. No. US 5252713
 DT Utility
 FS Granted
 INCL INCLM: 514/032.000
 INCL INCLS: 424/178.100; 514/008.000; 514/387.000; 530/350.000; 530/363.000;
 530/357.000; 530/370.000; 530/392.000; 530/409.000; 548/304.100
 NCL NCLM: 514/032.000
 NCLS: 424/178.100; 514/008.000; 514/387.000; 530/350.000; 530/363.000;
 530/370.000; 530/392.000; 530/409.000; 548/304.100
 IC (6)
 ICM: A61K031-415
 ICS: A61K047-42; A61K047-48
 EXF 514/2; 514/8; 514/387; 435/188; 530/350; 530/351; 530/362; 530/363;
 530/387.3; 530/392; 530/399; 530/391.7; 530/391.9; 530/402; 530/367;
 530/370; 530/409; 530/825; 424/85.91; 424/178.1; 548/303.7; 548/304.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 5 OF 5 USPATFULL
 AN 9415504 USPATFULL
 TI Method for prognosticating response to cancer therapy
 IN Bacus, Sarah S., Hinsdale, IL, United States
 PA Becton, Dickinson and Company, Franklin Lakes, NJ, United States (U.S.
 corporation)
 PI US 5288477 19940222
 AI US 1993-32529 19930315 (8)
 RLI Continuation of Ser. No. US 1991-767041, filed on 27 Sep 1991, now
 abandoned
 DT Utility
 FS Granted
 INCL INCLM: 424/002.000
 INCL INCLS: 424/035.500; 435/007.100; 436/501.000
 NCL NCLM: 435/007.230
 NCLS: 424/035.500; 435/007.100; 435/029.000; 436/501.000
 IC (5)
 ICM: G01N001-00
 ICS: G01N033-48; G01N033-566; C12Q001-68
 EXF 424/2; 424/85.8; 435/7.1; 436/501
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 => d his
 (FILE 'HOME' ENTERED AT 10:53:01 ON 05 NOV 2002)
 FILE 'MEDLINE, CANCELRIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
 ENTERED AT 10:53:32 ON 05 NOV 2002
 L1 9309 S HER2 OR ERB2 OR CERBB2 OR P185

L2 3941 S L1 AND ANTIBODY
 L3 503 S L2 AND CHEMOTHERAPEUTIC?
 L4 418 DUP REM L3 (85 DUPLICATES REMOVED)
 L5 5 S L4 NOT PY=>1996

 => s l1 and antibody
 L6 3941 L1 AND ANTIBODY

 => s l6 and chemo?
 L7 1252 L6 AND CHEMO?

 => s l7 and cancer
 L8 1178 L7 AND CANCER

 => s l8 and colorectal
 L9 206 L8 AND COLORECTAL

 => dup rem l9
 PROCESSING COMPLETED FOR L9
 L10 204 DUP REM L9 (2 DUPLICATES REMOVED)

 '1996' NOT A VALID FIELD CODE
 6 FILES SEARCHED...
 L11 0 L10 NOT PY=> 1996

 => d l10 1-50

 L10 ANSWER 1 OF 204 USPATFULL
 AN 2002:289327 USPATFULL
 TI Compositions and methods for the diagnosis and treatment of tumor
 IN Ashkenazi, Avi, San Mateo, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Godowski, Paul J., Burlingame, CA, UNITED STATES
 Gurney, Austin, Belmont, CA, UNITED STATES
 Polakis, Paul, Burlingame, CA, UNITED STATES
 Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 Wu, Thomas D., San Francisco, CA, UNITED STATES
 Zhang, Zemin, Foster City, CA, UNITED STATES
 GEMENTECH, INC. (U.S. corporation)
 US 2002161199 A1 20021031
 US 2001-938418 A1 20010823 (9)
 Continuation of Ser. No. WO 1999-US5028, filed on 8 Mar 1999, UNKNOWN
 Continuation of Ser. No. WO 1999-US12252, filed on 2 Jun 1999, UNKNOWN
 Continuation of Ser. No. WO 1999-US20111, filed on 1 Sep 1999, UNKNOWN
 Continuation of Ser. No. WO 1999-US28565, filed on 2 Dec 1999, UNKNOWN
 Continuation of Ser. No. WO 2000-US4342, filed on 18 Feb 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US4341, filed on 18 Feb 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US5841, filed on 2 Mar 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US8439, filed on 30 Mar 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US14042, filed on 22 May 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US23328, filed on 24 Aug 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US32678, filed on 1 Dec 2000, UNKNOWN
 Continuation of Ser. No. WO 2001-US6520, filed on 28 Feb 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US17800, filed on 1 Jun 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US19692, filed on 20 Jun 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US21066, filed on 29 Jun 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US21735, filed on 9 Jul 2001, UNKNOWN
 US 1998-81071P 19980408 (60)
 US 1998-85697P 19980515 (60)
 US 1998-97022P 19980818 (60)
 US 1998-101922P 19980924 (60)
 US 1998-103679P 19981008 (60)
 Utility
 PRAI

 L10 ANSWER 2 OF 264 USPATFULL
 AN 2002:280841 USPATFULL
 TI Pyrrole substituted 2-indolinone protein kinase inhibitors
 IN Tang, Peng Cho, Moraga, CA, UNITED STATES
 Miller, Todd A., Bend, OR, UNITED STATES
 Li, Xiaoyuan, Los Altos, CA, UNITED STATES
 Sun, Li, Foster City, CA, UNITED STATES
 Wei, Chung Chen, Foster City, CA, UNITED STATES
 Shirazian, Shahrzad, Corte Madera, CA, UNITED STATES
 Liang, Congxin, Sunnyvale, CA, UNITED STATES
 Vojtkovsky, Tomas, San Francisco, CA, UNITED STATES
 Nematala, Asaad S., Concord, CA, UNITED STATES
 Hawley, Michael, Kalamazoo, MI, UNITED STATES
 PI US 2002156292 A1 20021024
 AI US 2001-783264 A1 20010215 (9)
 PRAI US 2000-182710P 20000215 (60)
 US 2000-216422P 20000706 (60)
 US 2000-243532P 20001027 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 7280
 INCL INCLM: 548/487.000
 NCL NCLM: 548/487.000
 IC [7]
 ICM: C07D043-02

 L10 ANSWER 3 OF 204 USPATFULL
 AN 2002:280802 USPATFULL
 TI Novel Stra6 polypeptides
 IN Pennica, Diane, Burlingame, CA, UNITED STATES
 Smith, Victoria, Burlingame, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 PI US 2002156252 A1 20021024
 AI US 2001-759056 A1 20010111 (9)
 PRAI US 2000-228914P 20000829 (60)
 US 2000-197039P 20000414 (60)
 US 2000-175849P 20000113 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6615
 INCL INCLM: 536/023.100
 NCL NCLM: 536/023.100
 IC [7]
 ICM: C07H021-02
 ICS: C07H021-04

 L10 ANSWER 4 OF 204 USPATFULL
 AN 2002:280599 USPATFULL
 TI Use of EXT genes for the treatment of cancer and other diseases
 IN Tufaro, Frank, Vancouver, CANADA
 McCormick, M. Craig, Vancouver, CANADA
 PA University of British Columbia, Vancouver, CANADA (U.S. corporation)
 PI US 2002156044 A1 20021024
 AI US 2002-106092 A1 20020325 (10)

RLI Continuation of Ser. No. US 1998-60940, filed on 15 Apr 1998, PENDING
 DT Utility
 FS APPLICATION
 PI LN.CNT 1597
 INCL INCLM: 514/044.000
 INCLS: 435/456.000; 514/056.000
 NCL NCLM: 514/044.000
 NCLS: 435/456.000; 514/056.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K031-727; C12N015-86; C12N015-861; C12N015-867

LI0 ANSWER 5 OF 204 USPATFULL
 AN 2002:280588 USPATFULL
 TI Immunostimulatory nucleic acids and cancer medicament
 IN Bratzler, Robert L., Concord, MA, UNITED STATES
 PI Petersen, Deanna M., Newton, MA, UNITED STATES
 AI US 2002156033 AI 20021024
 PRAI US 2001-800266 AI 20010305 (9)
 DT US 2000-187214P 20000303 (60)
 FS Utility
 LN.CNT 3220
 INCL INCLM: 514/044.000
 INCLS: 514/008.000; 514/050.000; 514/251.000; 424/085.500; 424/277.100;
 NCL NCLM: 514/449.000; 514/509.000
 NCLS: 514/008.000; 514/050.000; 514/251.000; 424/085.500; 424/277.100;
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-21; A61K039-00; A61K038-16

LI0 ANSWER 6 OF 204 USPATFULL
 AN 2002:280561 USPATFULL
 TI Secreted and transmembrane polypeptides and nucleic acids encoding the same
 IN Ashkenazi, Avi, San Mateo, CA, UNITED STATES
 Baker, Kevin P., Barnestown, MD, UNITED STATES
 Botstein, David, Belmont, CA, UNITED STATES
 Desnoyers, Luc, San Francisco, CA, UNITED STATES
 Eaton, Dan L., San Rafael, CA, UNITED STATES
 Ferrara, Napoleone, San Francisco, CA, UNITED STATES
 Filvaroff, Ellen, San Francisco, CA, UNITED STATES
 Fong, Sherman, Alameda, CA, UNITED STATES
 Gao, Wei-Qiang, Palo Alto, CA, UNITED STATES
 Gerber, Hanspeter, San Francisco, CA, UNITED STATES
 Gerritsen, Mary E., San Mateo, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Godowski, Paul J., Burlingame, CA, UNITED STATES
 Gromaldi, J. Christopher, San Francisco, CA, UNITED STATES
 Gurney, Austin L., Belmont, CA, UNITED STATES
 Hillan, Kenneth J., San Francisco, CA, UNITED STATES
 Kijavini, Ivar J., Lafayette, CA, UNITED STATES
 Kuo, Sophia S., San Francisco, CA, UNITED STATES
 Napier, Mary A., Hillsborough, CA, UNITED STATES
 Pan, James, Belmont, CA, UNITED STATES
 Paoni, Nicholas F., Belmont, CA, UNITED STATES
 Roy, Margaret Ann, San Francisco, CA, UNITED STATES
 Shelton, David L., Oakland, CA, UNITED STATES
 Stewart, Timothy A., San Francisco, CA, UNITED STATES
 Tumas, Daniel, Orinda, CA, UNITED STATES
 Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES

Genentech, Inc. (U.S. corporation)
 PA US 2002156006 AI 20021024
 PI US 2001-978295 AI 20011015 (9)
 RLI Continuation of Ser. No. US 1998-40220, filed on 17 Mar 1998, PENDING
 Continuation of Ser. No. US 1998-105413, filed on 26 Jun 1998, PENDING
 Continuation of Ser. No. US 1998-168978, filed on 7 Oct 1998, PENDING
 Continuation of Ser. No. US 1998-184216, filed on 2 Nov 1998, ABANDONED
 Continuation of Ser. No. US 1998-187368, filed on 6 Nov 1998, PENDING
 Continuation of Ser. No. US 1998-202054, filed on 7 Dec 1998, PENDING
 Continuation of Ser. No. US 1998-218517, filed on 22 Dec 1998, ABANDONED
 Continuation of Ser. No. US 1999-254465, filed on 5 Mar 1999, PENDING
 Continuation of Ser. No. US 1999-265686, filed on 10 Mar 1999, PENDING
 Continuation of Ser. No. US 1999-267213, filed on 12 Mar 1999, ABANDONED
 Continuation of Ser. No. US 1999-284291, filed on 12 Apr 1999, ABANDONED
 Continuation of Ser. No. US 1999-311832, filed on 14 May 1999, PENDING
 Continuation of Ser. No. US 380137, PENDING Continuation of Ser. No. US
 1999-380138, filed on 25 Aug 1999, PENDING Continuation of Ser. No. US
 1999-380142, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US
 2000-709238, filed on 8 Nov 2000, PENDING Continuation of Ser. No. US
 2000-723749, filed on 27 Nov 2000, PENDING Continuation of Ser. No. US
 2000-747259, filed on 20 Dec 2000, PENDING Continuation of Ser. No. US
 2001-816744, filed on 22 Mar 2001, PENDING Continuation of Ser. No. US
 2001-816920, filed on 22 Mar 2001, PENDING Continuation of Ser. No. US
 2001-854280, filed on 10 May 2001, PENDING Continuation of Ser. No. US
 2001-854298, filed on 10 May 2001, PENDING Continuation of Ser. No. US
 2001-872035, filed on 1 Jun 2001, PENDING Continuation of Ser. No. US
 2001-874503, filed on 5 Jun 2001, PENDING Continuation of Ser. No. US
 2001-882636, filed on 14 Jun 2001, PENDING Continuation of Ser. No. US
 2001-886342, filed on 19 Jun 2001, PENDING Continuation of Ser. No. US
 2001-918585, filed on 30 Jun 2001, PENDING
 PRAI WO 1998-US21141 19981007
 WO 1998-US24855 19981120
 WO 1999-US106 19990105
 WO 1999-US5028 19990308
 WO 1999-US5190 19990310
 WO 1999-US10733 19990514
 WO 1999-US28313 19990602
 WO 1999-US28551 19991130
 WO 1999-US28551 19991202
 WO 1999-US28565 19991202
 WO 1999-US30095 19991216
 WO 1999-US31243 19991230
 WO 1999-US31274 19991230
 WO 2000-US219 20000105
 WO 2000-US277 20000106
 WO 2000-US376 20000106
 WO 2000-US3555 20000211
 WO 2000-US4341 20000218
 WO 2000-US5841 20000302
 WO 2000-US7532 20000321
 WO 2000-US5034 20000224
 WO 2000-US6319 20000310
 WO 2000-US8439 20000330
 WO 2000-US13705 20000517
 WO 2000-US14042 20000522
 WO 2000-US14941 20000530
 WO 2000-US15264 20000602
 WO 2000-US20710 20000628
 WO 2000-US23328 20000824
 WO 2000-US32678 20001201
 WO 2000-US34956 20001220
 WO 2001-US6520 20010228
 WO 2001-US9552 20010322
 WO 2001-US17092 20010325
 WO 2001-US17800 20010601

WO 2001-US19692 20010620
WO 2001-US21066 20010629
WO 2001-US21735 20010709
US 1997-62250P 19971017 (60)
US 1997-64249P 19971103 (60)
US 1997-65311P 19971113 (60)
US 1997-66364P 19971121 (60)
US 1998-77450P 19980310 (60)
US 1998-77632P 19980311 (60)
US 1998-77641P 19980311 (60)
US 1998-77649P 19980311 (60)
US 1998-77791P 19980312 (60)
US 1998-78004P 19980313 (60)
US 1998-78886P 19980320 (60)
US 1998-78936P 19980320 (60)
US 1998-78910P 19980320 (60)
US 1998-78939P 19980320 (60)
US 1998-79294P 19980325 (60)
US 1998-79656P 19980326 (60)
US 1998-79664P 19980327 (60)
US 1998-79689P 19980327 (60)
US 1998-79663P 19980327 (60)
US 1998-79728P 19980327 (60)
US 1998-79786P 19980327 (60)
US 1998-79920P 19980330 (60)
US 1998-79923P 19980330 (60)
DT Utility
FS APPLICATION
LN.CNT 4995
INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/388.100; 536/023.200; 435/007.100; 435/069.100;
435/183.000; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 530/388.100; 536/023.200; 435/007.100; 435/069.100;
435/183.000; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: G01N033-53; C07H021-04; C12N009-00; C12P021-02; C12N005-06;
C07K014-435; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 204 USPATFULL
AN 2002:280029 USPATFULL
TI Prostate polynucleotides and uses
IN Sun, Zairen, Rockville, MD, UNITED STATES
Li, Xuan, Silver Spring, MD, UNITED STATES
Jay, Gilbert, North Bethesda, MD, UNITED STATES
PI US 2002:5463 Al 20021024
AI US 2001-996956 Al 20011130 (9)
PRAI US 2000-250354P 20001201 (60)
DT Utility
FS APPLICATION
LN.CNT 2288
INCL INCLM: 435/006.000
INCLS: 536/024.300; 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/024.300; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04

L10 ANSWER 8 OF 204 USPATFULL
AN 2002:273380 USPATFULL
TI Methods for treating proliferative diseases
IN Emanuel, David J., Tenafly, NJ, UNITED STATES

WO 2001-US19692 20010620
WO 2001-US21066 20010629
WO 2001-US21735 20010709
US 1997-62250P 19971017 (60)
US 1997-64249P 19971103 (60)
US 1997-65311P 19971113 (60)
US 1997-66364P 19971121 (60)
US 1998-77450P 19980310 (60)
US 1998-77632P 19980311 (60)
US 1998-77641P 19980311 (60)
US 1998-77649P 19980311 (60)
US 1998-77791P 19980312 (60)
US 1998-78004P 19980313 (60)
US 1998-78886P 19980320 (60)
US 1998-78936P 19980320 (60)
US 1998-78910P 19980320 (60)
US 1998-78939P 19980320 (60)
US 1998-79294P 19980325 (60)
US 1998-79656P 19980326 (60)
US 1998-79664P 19980327 (60)
US 1998-79689P 19980327 (60)
US 1998-79663P 19980327 (60)
US 1998-79728P 19980327 (60)
US 1998-79786P 19980327 (60)
US 1998-79920P 19980330 (60)
US 1998-79923P 19980330 (60)
DT Utility
FS APPLICATION
LN.CNT 4995
INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/388.100; 536/023.200; 435/007.100; 435/069.100;
435/183.000; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 530/388.100; 536/023.200; 435/007.100; 435/069.100;
435/183.000; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: G01N033-53; C07H021-04; C12N009-00; C12P021-02; C12N005-06;
C07K014-435; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 204 USPATFULL
AN 2002:266439 USPATFULL
TI NSP molecules
IN Stewart, Timothy A., San Francisco, CA, UNITED STATES
Lu, Yamei, Foster City, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002:147322 Al 20021010
AI US 2001-931087 Al 20010815 (9)
RLI Division of Ser. No. US 1999-367206, filed on 9 Aug 1999, PATENTED
PRAI WO 1999-US8847 19990423
US 1998-82767P 19980423 (60)
US 1998-113296P 19981222 (60)
DT Utility
FS APPLICATION
LN.CNT 6046
INCL INCLM: 536/023.200
INCLS: 435/006.000; 435/007.230; 435/325.000; 435/320.100; 435/069.100;
435/183.000
NCL NCLM: 536/023.200
NCLS: 435/006.000; 435/007.230; 435/325.000; 435/320.100; 435/069.100;
435/183.000
IC [7]
ICM: C07H021-04

Tendler, Craig L., Teaneck, NJ, UNITED STATES
Schering Corporation (2)
PI US 2002:151503 Al 20021017
AI US 2002-67443 Al 20020205 (10)
PRAI US 2001-267807P 20010209 (60)
DT Utility
FS APPLICATION
LN.CNT 902
INCL INCLM: 514/034.000
INCLS: 424/450.000
NCL NCLM: 514/034.000
NCLS: 424/450.000
IC [7]
ICM: A61K031-704
ICS: A61K009-127

L10 ANSWER 9 OF 204 USPATFULL
AN 2002:272474 USPATFULL
TI Compositions for treatment of melanoma and method of using same
IN Houghton, Alan N., New York, NY, UNITED STATES
Bergman, Philip J., Tarrytown, NY, UNITED STATES
Wolchok, Jedd D., New York, NY, UNITED STATES
PI US 2002:150589 Al 20021017
AI US 2001-996128 Al 20011127 (9)
RLI Continuation-in-part of Ser. No. US 2000-627694, filed on 28 Jul 2000,
PENDING Continuation-in-part of Ser. No. US 1999-308697, filed on 21 May
1999, GRANTED, Pat. No. US 6328969 A 371 of International Ser. No. WO
1997-US22669, filed on 10 Dec 1997, UNKNOWN
PRAI US 1997-36419P 19970218 (60)
US 1996-32535P 19961210 (60)
US 2000-180651P 20000126 (60)
DT Utility
FS APPLICATION
LN.CNT 780
INCL INCLM: 424/185.100
INCLS: 435/226.000
NCL NCLM: 424/185.100
NCLS: 435/226.000
IC [7]
ICM: A61K039-00
ICS: C12N009-64

L10 ANSWER 10 OF 204 USPATFULL
AN 2002:266439 USPATFULL
TI NSP molecules
IN Stewart, Timothy A., San Francisco, CA, UNITED STATES
Lu, Yamei, Foster City, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002:147322 Al 20021010
AI US 2001-931087 Al 20010815 (9)
RLI Division of Ser. No. US 1999-367206, filed on 9 Aug 1999, PATENTED
PRAI WO 1999-US8847 19990423
US 1998-82767P 19980423 (60)
US 1998-113296P 19981222 (60)
DT Utility
FS APPLICATION
LN.CNT 6046
INCL INCLM: 536/023.200
INCLS: 435/006.000; 435/007.230; 435/325.000; 435/320.100; 435/069.100;
435/183.000
NCL NCLM: 536/023.200
NCLS: 435/006.000; 435/007.230; 435/325.000; 435/320.100; 435/069.100;
435/183.000
IC [7]
ICM: C07H021-04

ICS: C120001-68; GO1N033-574; C12P021-02; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 204 USPTFULL
AN 2002:265970 USPTFULL
TI Novel method for the stabilization of chimeric immunoglobulins or
immunoglobulin fragments, and stabilized anti-EGF-2 scfv fragment
IN Pluckhuhn, Andreas, Zurich, SWITZERLAND
Honegger, Annemarie, Berlin, GERMANY, FEDERAL REPUBLIC OF
Willuda, Jorg, Zurich, GERMANY, FEDERAL REPUBLIC OF
PI US 2002:146846 A1 20021010
AI US 2001-971543 A1 20011004 (9)
RLI Continuation of Ser. No. WO 2000-EP3176, filed on 10 Apr 2000, UNKNOWN
PRAI EP 1999-107030 19990409
DT Utility
FS APPLICATION

LN.CNT 1663
INCL INCLM: 436/518.000
INCLS: 702/019.000; 435/069.100
NCL NCLM: 436/518.000
NCLS: 702/019.000; 435/069.100
IC [7]
ICM: GO1N033-543

ICS: G06F019-00; GO1N033-48; GO1N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 204 USPTFULL
AN 2002:265931 USPTFULL
TI Cardiotropin-1 compositions and methods for the treatment of tumor
IN Botstein, David, Belmont, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Lawrence, David A., San Francisco, CA, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Roy, Margaret Ann, San Francisco, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Genentech, Inc. (U.S. corporation)
PI US 2002:146707 A1 20021010
AI US 2001-901257 A1 20010709 (9)
RLI Continuation of Ser. No. US 2000-648252, filed on 25 Aug 2000, ABANDONED

Division of Ser. No. US 1999-234730, filed on 21 Jan 1999, ABANDONED
Division of Ser. No. US 1998-33114, filed on 2 Mar 1998, ABANDONED
Continuation of Ser. No. US 1996-733850, filed on 18 Oct 1996, ABANDONED
Continuation of Ser. No. US 1995-443129, filed on 17 May 1995, GRANTED,
Pat. No. US 5627073 Division of Ser. No. US 1994-286304, filed on 5 Aug
1994, GRANTED, Pat. No. US 5571893 Continuation-in-part of Ser. No. US
1994-233609, filed on 25 Apr 1994, GRANTED, Pat. No. US 5534615
PRAI US 1998-113298 19981222 (60)
DT Utility
FS APPLICATION

LN.CNT 3565
INCL INCLM: 435/006.000
INCLS: 435/007.230; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 536/023.200
IC [7]
ICM: C120001-68

ICS: GO1N033-574; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 204 USPTFULL
AN 2002:259486 USPTFULL
TI Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
IN Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
Tari, Ana M., Houston, TX, UNITED STATES
Lim, Soo-Jeong, Seoul, KOREA, REPUBLIC OF

PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002:143062 A1 20021003
AI US 2001-982113 A1 20011017 (9)
PRAI US 2000-241445P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3985
INCL INCLM: 514/613.000
INCLS: 424/155.100; 424/450.000
NCL NCLM: 514/613.000
NCLS: 424/155.100; 424/450.000
IC [7]
ICM: A61K039-395
ICS: A61K031-16; A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 204 USPTFULL
AN 2002:258758 USPTFULL
TI Method of determining a chemotherapeutic regimen by assaying
gene expression in primary tumors
IN Danenberg, Kathleen D., Altadena, CA, UNITED STATES
PI US 2002:142328 A1 20021003
AI US 2001-998333 A1 20011203 (9)
PRAI US 2000-250120P 20001201 (60)
US 2000-250472P 20001204 (60)
DT Utility
FS APPLICATION

LN.CNT 1617
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C120001-68

ICS: G06F019-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 204 USPTFULL
AN 2002:258426 USPTFULL
TI Apo-2 ligand-anti-Her-2 antibody synergism
IN Ashkenazi, Avi J., San Mateo, CA, UNITED STATES
Phillips, Gail Lewis, San Carlos, CA, UNITED STATES
GENENTECH, INC. (U.S. corporation)
PI US 2002:141993 A1 20021003
AI US 2002-107958 A1 20020326 (10)
RLI Continuation of Ser. No. US 1999-277252, filed on 26 Mar 1999, PENDING
PRAI US 1998-79683P 19980327 (60)
DT Utility
FS APPLICATION

LN.CNT 1596
INCL INCLM: 424/143.100
INCLS: 424/155.100; 600/001.000
NCL NCLM: 424/143.100
NCLS: 424/155.100; 600/001.000
IC [7]
ICM: A61K039-395

ICS: A61N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 204 USPTFULL
AN 2002:258375 USPTFULL
TI Prostate stem cell antigen and uses thereof
IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
Witte, Owen N., Sherman Oaks, CA, UNITED STATES
Saffran, Douglas C., Los Angeles, CA, UNITED STATES

PA Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
The Regents of the University of California and UroGenesys, Inc. (U.S. corporation)

PI US 2002141941 A1 20021003
US 2001-963620 A1 20010926 (9)
Division of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING

RLI Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999, PENDING
Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May 1999, PATENTED
Continuation-in-part of Ser. No. US 1999-251835, filed on 17 Feb 1999, PATENTED
Continuation-in-part of Ser. No. US 1998-203939, filed on 2 Dec 1998, PATENTED
Continuation-in-part of Ser. No. US 1998-38261, filed on 10 Mar 1998, PATENTED

PRAI US 1997-228816P 19970310 (60)
US 1998-71141P 19980112 (60)
US 1998-74675P 19980213 (60)
US 1998-113230P 19981221 (60)
US 1999-120536P 19990217 (60)
US 1999-124658P 19990316 (60)
Utility
APPLICATION
LN.CNT 5010
INCL INCLM: 424/001.490
INCLS: 424/155.100; 424/178.100
NCL NCLM: 424/001.490
NCLS: 424/155.100; 424/178.100
IC [7]
ICM: A61K051-00
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 204 USPTATFULL
AN 2002:251802 USPTATFULL
TI Tyrosine kinase inhibitors
IN Bilodeau, Mark T., Lansdale, PA, UNITED STATES
Hoffman, George D., Lansdale, PA, UNITED STATES
Hoffman, Jacob M., JR., Lansdale, PA, UNITED STATES
Sisko, John T., Lansdale, PA, UNITED STATES
Manley, Peter J., Harleysville, PA, UNITED STATES
Smith, Anthony M., Green Lane, PA, UNITED STATES
Tucker, Thomas J., North Wales, PA, UNITED STATES
Lumma, William C., JR., Helena, MT, UNITED STATES
Rodman, Leonard, New York, NY, UNITED STATES
US 2002137755 A1 20020926
US 2001-990473 A1 20011121 (9)
PRAI US 2000-251006P 20001204 (60)
Utility
APPLICATION
LN.CNT 3627
INCL INCLM: 514/256.000
INCLS: 514/269.000; 544/317.000; 544/327.000; 544/328.000
NCL NCLM: 514/256.000
NCLS: 514/269.000; 544/317.000; 544/327.000; 544/328.000
IC [7]
ICM: A61K031-506
ICS: C07D417-02; C07D413-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 204 USPTATFULL
AN 2002:251730 USPTATFULL
TI C-eki oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
IN Hogan, Kevin T., Charlottesville, VA, UNITED STATES
Ross, Mark M., Charlottesville, VA, UNITED STATES
PI US 2002137683 A1 20020926
AI US 2001-753831 A1 20010103 (9)

PRAI US 2000-174236P 20000103 (60)
DT Utility
FS APPLICATION
LN.CNT 2293
INCL INCLM: 514/015.000
INCLS: 514/044.000; 536/023.100; 530/328.000
NCL NCLM: 514/015.000
NCLS: 514/044.000; 536/023.100; 530/328.000
IC [7]
ICM: A61K048-00
ICS: A61K038-08; C07H021-04; C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 204 USPTATFULL
AN 2002:250751 USPTATFULL
TI PSCA: prostate stem cell antigen and uses thereof
IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
Witte, Owen N., Sherman Oaks, CA, UNITED STATES
Saffran, Douglas C., Los Angeles, CA, UNITED STATES
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
The Regents of the University of California (U.S. corporation)
US 2002136689 A1 20020926
US 2001-934773 A1 20010821 (9)
Continuation of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999, PENDING
Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May 1999, PATENTED
Continuation-in-part of Ser. No. US 1998-203939, filed on 2 Dec 1998, PATENTED
Continuation-in-part of Ser. No. US 1998-38261, filed on 10 Mar 1998, PATENTED

PRAI US 1997-228816P 19970310 (60)
US 1998-71141P 19980112 (60)
US 1998-74675P 19980213 (60)
US 1998-113230P 19981221 (60)
US 1999-120536P 19990217 (60)
US 1999-124658P 19990316 (60)
Utility
APPLICATION
LN.CNT 5011
INCL INCLM: 424/001.490
INCLS: 424/155.100; 424/178.100; 530/388.800; 530/391.100
NCL NCLM: 424/001.490
NCLS: 424/155.100; 424/178.100; 530/388.800; 530/391.100
IC [7]
ICM: A61K051-00
ICS: A61K039-395; C07K016-30; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 204 USPTATFULL
AN 2002:243088 USPTATFULL
TI Diagnostic and monitoring methods for cancer
IN Nevalainen, Marja T., Rockville, MD, UNITED STATES
Rui, Hallgeir, Rockville, MD, UNITED STATES
PI US 2002132274 A1 20020919
AI US 2001-760899 A1 20010117 (9)
DT Utility
FS APPLICATION
LN.CNT 3189
INCL INCLM: 435/007.230
NCL NCLM: 435/007.230
IC [7]
ICM: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 204 USPTATFULL

AN 2002:243038 USPTATFULL
 TI Car receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
 IN Poznansky, Mark C., Charlestown, MA, UNITED STATES
 Sadden, David T., Weston, MA, UNITED STATES
 Olazak, Ivona T., Charlestown, MA, UNITED STATES
 Brown, Edward M., Milton, MA, UNITED STATES
 US 2002:132224 AI 20020919
 PI US 2001:2854 AI 20011101 (10)
 RLI Continuation-in-part of Ser. No. WO 2000-US15440, filed on 2 Jun 2000, UNKNOWN
 DT Utility
 FS APPLICATION
 LN.CNT 2510
 INCL INCLM: 435/004.000
 INCLS: 514/001.000
 NCL NCLM: 435/004.000
 NCLS: 514/001.000
 IC [7]
 ICM: A61K031-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 204 USPTATFULL
 AN 2002:236082 USPTATFULL
 TI Methods of inducing cancer cell death and tumor regression
 IN Daley, George Q., Weston, MA, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 2002:28280 AI 20020912
 AI US 2001:971545 AI 20011005 (9)
 PRAI US 2000:238240P 20001005 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1314
 INCL INCLM: 514/275.000
 INCLS: 514/290.000
 NCL NCLM: 514/275.000
 NCLS: 514/290.000
 IC [7]
 ICM: A61K031-505
 ICS: A61K031-473
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 23 OF 204 USPTATFULL
 AN 2002:235993 USPTATFULL
 TI Expression of properly folded and soluble extracellular domain of a gonadotropin receptor
 IN Lobel, Leslie, Riverdale, NY, UNITED STATES
 PI US 2002:28190 AI 20020912
 AI US 2001:804626 AI 20010309 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 2879
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 NCL NCLM: 514/012.000
 NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 IC [7]
 ICM: A61K038-00
 ICS: C12P021-02; C12N005-06; C07H021-04; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 24 OF 204 USPTATFULL
 AN 2002:227938 USPTATFULL
 TI Novel inhibitor of hepatocyte growth factor activator for use in

IN modulation of angiogenesis and cardiovascularization
 Gurney, Austin L., Belmont, CA, UNITED STATES
 Kirchofer, Daniel K., Los Altos, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 GENENTECH, INC. (U.S. corporation)
 PI US 2002:123031 AI 20020905
 AI US 2000-742291 AI 20001219 (9)
 PRAI WO 2000-US3555 20000211
 WO 2000-US6834 20000315
 US 2000-253655P 20001128 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6377
 INCL INCLM: 435/069.100
 INCLS: 514/002.000; 435/007.210; 530/387.900; 435/320.100; 514/044.000;
 NCL NCLM: 435/069.100
 NCLS: 514/002.000; 435/007.210; 530/387.900; 435/320.100; 514/044.000;
 IC [7]
 ICM: A01N037-18
 ICS: A61K038-00; G01N033-567; C07H021-04; A61K031-70; A01N043-04;
 C12P021-06; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74;
 C12N005-00; C12N005-02; C07K016-00; C12P021-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 25 OF 204 USPTATFULL
 AN 2002:227642 USPTATFULL
 TI Heparinase III and uses thereof
 IN Liu, Dongfang, Framingham, MA, UNITED STATES
 Pojasek, Kevin, Cambridge, MA, UNITED STATES
 Shriver, Zachary, Cambridge, MA, UNITED STATES
 Holley, Kristine, Boston, MA, UNITED STATES
 El-Shabrawi, Yusuf, Graz, AUSTRIA
 Venkataraman, Ganesh, Wallham, MA, UNITED STATES
 Saeisckharan, Ram, Cambridge, MA, UNITED STATES
 PI US 2002:122793 AI 20020905
 AI US 2001-802285 AI 20010308 (9)
 PRAI US 2000-187846P 20000308 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3154
 INCL INCLM: 424/094.610
 NCL NCLM: 424/094.610
 IC [7]
 ICM: A61K038-47
 ICS: C12N003-24
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 26 OF 204 USPTATFULL
 AN 2002:221022 USPTATFULL
 TI PSCA: prostate stem cell antigen and uses thereof
 IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
 Witte, Owen N., Sherman Oaks, CA, UNITED STATES
 Saffran, Douglas C., Los Angeles, CA, UNITED STATES
 Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
 PI US 2002:19157 AI 20020829
 AI US 2001-854611 AI 20010514 (9)
 RLI Division of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May
 1999, PATENTED Continuation-in-part of Ser. No. US 1999-251835, filed on
 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1998-203939,
 filed on 2 Dec 1998, PATENTED Continuation-in-part of Ser. No. US
 1998-38261, filed on 10 Mar 1998, PATENTED

PRAI US 1999-124658P 19990316 (60)
 US 1999-120536P 19990217 (60)
 US 1998-113230P 19981221 (60)
 US 1998-74675P 19980213 (60)
 US 1998-71141P 19980112 (60)
 US 1997-228816P 19970310 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5019
 INCL INCLM: 424/155.100
 INCLS: 530/388.800
 NCL NCLM: 424/155.100
 NCLM: 530/388.800
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-30
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 27 OF 204 USPATFULL
 AN 2002:213689 USPATFULL
 TI Differentially expressed epitopes and uses thereof
 IN Logtenberg, Ton, Werkhoven, NETHERLANDS
 Cilenti, Lucia, Rome, ITALY
 Bloem, Andries Christiaan, Driebergen, NETHERLANDS
 Zwijssen, Renate Marie Louise, Utrecht, NETHERLANDS
 PI US 2002115065 Al 20020822
 AI US 2001-940386 Al 20010827 (9)
 PRAI US 2000-228429P 20000828 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2795
 INCL INCLM: 435/005.000
 INCLS: 435/007.100; 435/007.210; 435/007.320; 435/006.000
 NCL NCLM: 435/005.000
 NCLM: 435/007.100; 435/007.210; 435/007.320; 435/006.000
 IC [7]
 ICM: C12Q001-70
 ICS: C12Q001-68; G01N033-53; G01N033-567; G01N033-554; G01N033-569
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 28 OF 204 USPATFULL
 AN 2002:205851 USPATFULL
 TI Methods and products for tumor immunotherapy using cytokines
 IN Mathowitz, Edith, Brookline, MA, UNITED STATES
 Jong, Yong S., Providence, RI, UNITED STATES
 Egilmez, Nejat K., E. Amherst, NY, UNITED STATES
 Bankert, Richard B., Eden, NY, UNITED STATES
 PA Jacob, Jules S., Taunton, MA, UNITED STATES
 Health Research, Inc. (U.S. Corporation)
 PI US 2002110538 Al 20020815
 AI US 2000-749649 Al 20001227 (9)
 PRAI US 1999-173236P 19991228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1955
 INCL INCLM: 424/085.100
 INCLS: 424/491.000
 NCL NCLM: 424/085.100
 NCLM: 424/491.000
 IC [7]
 ICM: A61K038-19
 ICS: A61K009-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 29 OF 204 USPATFULL

2002:191601 USPATFULL
 PSCA: prostate stem cell antigen and uses thereof
 TI Reiter, Robert E., Los Angeles, CA, UNITED STATES
 IN Witte, Owen N., Sherman Oaks, CA, UNITED STATES
 Saffran, Douglas C., Los Angeles, CA, UNITED STATES
 Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
 The Regents of the University of California (U.S. corporation)
 PI US 2002102666 Al 20020801
 AI US 2001-855153 Al 20010514 (9)
 RLI Division of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May
 1999, PATENTED Continuation-in-part of Ser. No. US 1999-251835, filed on
 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1998-203939,
 filed on 2 Dec 1998, PATENTED Continuation-in-part of Ser. No. US
 1998-38261, filed on 10 Mar 1998, PATENTED
 PRAI US 1997-228816P 19970310 (60)
 US 1998-71141P 19980112 (60)
 US 1998-74675P 19980213 (60)
 US 1998-113230P 19981221 (60)
 US 1999-120536P 19990217 (60)
 US 1999-124658P 19990316 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5002
 INCL INCLM: 435/110.000
 INCLS: 424/178.100; 424/001.490; 530/389.100
 NCL NCLM: 435/110.000
 NCLM: 424/178.100; 424/001.490; 530/389.100
 IC [7]
 ICM: A61K039-395
 ICS: A61K051-00; C07K016-46
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 30 OF 204 USPATFULL
 AN 2002:191557 USPATFULL
 TI Cardiotrophin-1 compositions and methods for the treatment of tumor
 IN Botstein, David, Belmont, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Lawrence, David A., San Francisco, CA, UNITED STATES
 Pennica, Diane, Burlingame, CA, UNITED STATES
 Roy, Margaret Ann, San Francisco, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 PA Genentech, Inc. (U.S. corporation)
 PI US 2002102622 Al 20020801
 AI US 2001-901540 Al 20010709 (9)
 RLI Continuation of Ser. No. US 2000-648258, filed on 25 Aug 2000, ABANDONED
 Division of Ser. No. US 1999-234730, filed on 21 Jan 1999, ABANDONED
 Division of Ser. No. US 1998-33114, filed on 2 Mar 1998, ABANDONED
 Continuation of Ser. No. US 1996-733850, filed on 18 Oct 1996, ABANDONED
 Continuation of Ser. No. US 1995-443129, filed on 17 May 1995, PATENTED
 Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, PATENTED
 Continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994,
 PATENTED
 PRAI US 1998-113296P 19981222 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3559
 INCL INCLM: 435/007.230
 INCLS: 435/226.000; 435/069.100; 435/252.300; 435/254.100; 435/325.000;
 435/320.100; 536/023.200
 NCL NCLM: 435/007.230
 NCLM: 435/226.000; 435/069.100; 435/252.300; 435/254.100; 435/325.000;
 435/320.100; 536/023.200
 IC [7]

ICM: G01N033-574
ICS: C07H021-04; C12N009-64; C12N001-18; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 204 USPATFULL
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bouguieret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002:102604 A1 2002:0801
AI US 2000-731872 A1 2000:1207 (9)
PRAI US 1999-169629P 1999:1208 (60)
US 2000-187470P 2000:0306 (60)
DT Utility
FS APPLICATION
LN.CNT 28061
INCL INCLM: 435/007.100
INCL INCLS: 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCL NCLS: 536/023.100; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 204 USPATFULL
AN 2002:191479 USPATFULL
TI Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
IN Mack, David, Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
Wilson, Keith E., Redwood City, CA, UNITED STATES
PI US 2002:102544 A1 2002:0801
AI US 2000-733757 A1 2000:1208 (9)
RLI Continuation-in-part of Ser. No. US 2000-663733, filed on 15 Sep 2000,
DT Utility
FS APPLICATION
LN.CNT 3191
INCL INCLM: 435/006.000
INCL INCLS: 435/007.230
NCL NCLM: 435/006.000
NCL NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 204 USPATFULL
AN 2002:191201 USPATFULL
TI Uses of monoclonal antibody 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
PI US 2002:102264 A1 2002:0801
AI US 2001-982645 A1 2001:1018 (9)
PRAI US 2000-241344P 2000:1018 (60)
DT Utility
FS APPLICATION
LN.CNT 6128
INCL INCLM: 424/155.100
INCL INCLS: 424/178.100; 530/389.100; 435/326.000
NCL NCLM: 424/155.100
NCL NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]

ICM: A61K039-395
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 204 USPATFULL
AN 2002:185279 USPATFULL
TI Vascular endothelial cell growth factor antagonists
IN Ferrara, Napoleone, San Francisco, CA, UNITED STATES
Kim, Kyung Jin, San Francisco, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002:098187 A1 2002:0725
AI US 2002-104427 A1 2002:0321 (10)
RLI Continuation of Ser. No. US 1997-970591, filed on 14 Nov 1997, ABANDONED
Continuation-in-part of Ser. No. US 1995-378912, filed on 25 Jan 1995,
ABANDONED Continuation of Ser. No. US 1993-143908, filed on 26 Oct 1993,
ABANDONED Continuation of Ser. No. US 1992-968028, filed on 28 Oct 1992,
ABANDONED Continuation-in-part of Ser. No. US 1991-677215, filed on 29
Mar 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1258
INCL INCLM: 424/145.100
NCL NCLM: 424/145.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 35 OF 204 USPATFULL
AN 2002:171960 USPATFULL
TI Modified carboxypeptidase enzymes and their use
IN Begent, Richard H. J., London, UNITED KINGDOM
Chester, Kerry, London, UNITED KINGDOM
Minton, Nigel P., Wiltshire, UNITED KINGDOM
Rees, Anthony R., Bath, UNITED KINGDOM
Sharma, Surinder K., London, UNITED KINGDOM
Spencer, Daniel I. R., Hertfordshire, UNITED KINGDOM
PI US 2002:090709 A1 2002:0711
AI US 2001-698461 A1 2001:0705 (9)
PRAI US 2000-216689P 2000:0707 (60)
DT Utility
FS APPLICATION
LN.CNT 1212
INCL INCLM: 435/236.000
INCL INCLS: 435/069.700; 435/320.100; 435/325.000; 536/023.200; 435/254.200
NCL NCLM: 435/236.000
NCL NCLS: 435/069.700; 435/320.100; 435/325.000; 536/023.200; 435/254.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-04; C12N001-18; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 36 OF 204 USPATFULL
AN 2002:164793 USPATFULL
TI Agents for treating malignant diseases using the protein YB-1
IN Holm, Per Sonne, Munchen, GERMANY, FEDERAL REPUBLIC OF
Royer, Hans-Dieter, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
Dietel, Manfred, Berlin, GERMANY, FEDERAL REPUBLIC OF
Lage, Hermann, Berlin, GERMANY, FEDERAL REPUBLIC OF
Ladhoff, Axel, Bergfelde, GERMANY, FEDERAL REPUBLIC OF
Jurchoff, Stephan, Altlandsberg, GERMANY, FEDERAL REPUBLIC OF
Bergmann, Stephan, Berlin, GERMANY, FEDERAL REPUBLIC OF
Brand, Karsten, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2002:086411 A1 2002:0704
AI US 2001-29574 A1 2001:1220 (10)
RLI Continuation-in-part of Ser. No. WO 2000-DE1978, filed on 20 Jun 2000,

UNKNOWN
PRAI DE 1999-19929569 19990621
DT Utility
FS APPLICATION
LN.CNT 354
INCL INCLM: 435/235.100
NCL INCLS: 424/093.210; 435/456.000
NCLM: 435/235.100
NCLS: 424/093.210; 435/456.000
IC [7]
ICM: A61K048-00
ICS: C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 37 OF 204 USPTAFULL
AN 2002:164666 USPTAFULL
TI Methods for the treatment of cellular proliferative disorders
IN Coffey, Matthew C., Calgary, CANADA
PI US 2002086284 A1 20020704
AI US 2001-985756 A1 20011106 (9)
PRAI US 2000-246728P 20001109 (60)
DT Utility
FS APPLICATION
LN.CNT 1374
INCL INCLM: 435/005.000
NCL INCLS: 435/007.230
NCLM: 435/005.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-70
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 38 OF 204 USPTAFULL
AN 2002:133829 USPTAFULL
TI Methods and compositions for inhibiting cell proliferative disorders
IN Chen, Hui, Palo Alto, CA, UNITED STATES
Gazit, Aviv, Jerusalem, ISRAEL
Levitzki, Alexander, Jerusalem, ISRAEL
Hirth, Klaus Peter, San Francisco, CA, UNITED STATES
Mann, Elaine, Alameda, CA, UNITED STATES
Shawver, Laura K., San Francisco, CA, UNITED STATES
Tsal, Jiaming, San Francisco, CA, UNITED STATES
Tang, Peng Cho, Moraga, CA, UNITED STATES
US 2002068687 A1 20020606
AI US 2001-953933 A1 20010918 (9)
RLI Continuation of Ser. No. US 2000-722149, filed on 22 Nov 2000, ABANDONED
Continuation of Ser. No. US 1998-70318, filed on 29 Apr 1998, ABANDONED
Continuation of Ser. No. US 1993-39967, filed on 7 Mar 1995, PATENTED
Continuation-in-part of Ser. No. US 1994-207933, filed on 7 Mar 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2876
INCL INCLM: 510/433.000
NCL INCLM: 510/433.000
IC [7]
ICM: C11D017-00

L10 ANSWER 39 OF 204 USPTAFULL
AN 2002:133430 USPTAFULL
TI Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
IN An, Gang, Oklahoma City, OK, UNITED STATES
Veitri, Robert, Oklahoma City, OK, UNITED STATES

UROCOR, INC. (U.S. corporation)
PA DE 2002068281 A1 20020606
PI US 2001-754016 A1 20010102 (9)
RLI Division of Ser. No. US 1999-247188, filed on 9 Feb 1999, GRANTED, Pat. No. US 6156515 Division of Ser. No. US 2000-579236, filed on 24 May 2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 3955
INCL INCLM: 435/006.000
NCL INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCLM: 435/006.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 40 OF 204 USPTAFULL
AN 2002:133200 USPTAFULL
TI Tissue specific adenoviral vectors
IN Henderson, Daniel R., Palo Alto, CA, UNITED STATES
Schnur, Eric R., Palo Alto, CA, UNITED STATES
PI US 2002068049 A1 20020606
AI US 2000-732169 A1 20001206 (9)
RLI Continuation of Ser. No. US 1998-151376, filed on 10 Sep 1998, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 3956
INCL INCLM: 424/093.210
NCL INCLS: 435/235.100; 435/320.100
NCLM: 424/093.210
NCLS: 435/235.100; 435/320.100
IC [7]
ICM: A61K048-00
ICS: C12N015-861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 41 OF 204 USPTAFULL
AN 2002:126293 USPTAFULL
TI Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies
IN Akita, Robert, Hayward, CA, UNITED STATES
Sliwowski, Mark, San Carlos, CA, UNITED STATES
Genentech, Inc. (U.S. corporation)
PA US 2002064805 A1 20020530
AI US 2001-825584 A1 20010404 (9)
RLI Division of Ser. No. US 1999-316981, filed on 24 May 1999, ABANDONED
Continuation of Ser. No. US 1997-827009, filed on 25 Mar 1997, PATENTED
PRAI US 1996-46850P 19960327 (60)
DT Utility
FS APPLICATION
LN.CNT 2149
INCL INCLM: 435/007.230
NCL INCLS: 424/141.100; 530/388.220
NCLM: 435/007.230
NCLS: 424/141.100; 530/388.220
IC [7]
ICM: G01N033-574
ICS: A61K039-395; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 42 OF 204 USPTAFULL
AN 2002:126273 USPTAFULL
TI Gene detection assay for improving the likelihood of an effective

IN response to an ErbB antagonist cancer therapy
PA Genentech Inc. (U.S. corporation)
PI US 2002064785 AI 20020530
AI US 2001-863101 AI 20010518 (9)
PRAI US 2000-205754P 20000519 (60)
DT Utility
FS APPLICATION
LN.CNT 1329
INCL INCLM: 435/006.000
INCL: 435/007.230; 514/449.000
NCL INCLM: 435/006.000
NCL: 435/007.230; 514/449.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; A61K031-337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 43 OF 204 USPTATFULL
AN 2002:119330 USPTATFULL
TI Compositions and methods for dendritic cell-based immunotherapy
IN Laus, Reiner, Bellevue, WA, UNITED STATES
Vidovic, Damir, Bellevue, WA, UNITED STATES
Graddis, Thomas, Seattle, WA, UNITED STATES
PI US 2002061310 AI 20020523
AI US 2001-821883 AI 20010330 (9)
PRAI US 2000-193504P 20000330 (60)
DT Utility
FS APPLICATION
LN.CNT 2865
INCL INCLM: 424/185.100
INCL: 530/350.000
NCL INCLM: 424/185.100
NCL: 530/350.000
IC [7]
ICM: A61K039-00
ICS: C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 44 OF 204 USPTATFULL
AN 2002:105676 USPTATFULL
TI Anti-IGE antibodies
IN Lowman, Henry B., El Granada, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
Jardieu, Paula M., San Mateo, CA, UNITED STATES
Lowe, John, Daly City, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002054878 AI 20020509
AI US 2001-920171 AI 20010801 (9)
RLI Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED,
Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2
Jul 1997, GRANTED, Pat. No. US 5994511
DT Utility
FS APPLICATION
LN.CNT 5846
INCL INCLM: 424/171.100
INCL: 424/130.100; 424/133.100; 536/023.530; 435/007.100; 530/387.300
NCL INCLM: 424/171.100
NCL: 424/130.100; 424/133.100; 536/023.530; 435/007.100; 530/387.300
IC [7]
ICM: G01N033-53
ICS: C07H021-04; A61K039-395; A61K039-40; A61K039-42; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 45 OF 204 USPTATFULL

AN 2002:99468 USPTATFULL
TI Indolnolone derivatives as protein kinase/phosphatase inhibitors
IN Tang, Peng Cho, Moraga, CA, UNITED STATES
Harris, G. Davis, San Francisco, CA, UNITED STATES
LI, Xiaoyuan, Los Altos, CA, UNITED STATES
PI US 2002052389 AI 20020502
AI US 2001-871700 AI 20010604 (9)
PRAI US 2000-209162P 20000602 (60)
DT Utility
FS APPLICATION
LN.CNT 6105
INCL INCLM: 514/233.500
INCL: 514/414.000; 435/007.100; 544/144.000; 548/468.000
NCL INCLM: 514/233.500
NCL: 514/414.000; 435/007.100; 544/144.000; 548/468.000
IC [7]
ICM: A61K031-5377
ICS: A61K031-404; C07D413-02; C07D043-02; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 46 OF 204 USPTATFULL
AN 2002:99407 USPTATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002052308 AI 20020502
AI US 2001-925301 AI 20010810 (9)
RLI Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LN.CNT 30577
INCL INCLM: 514/001.000
INCL: 530/350.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100;
NCL INCLM: 514/001.000
NCL: 530/350.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100;
IC [7]
ICM: A61K031-00
ICS: C12Q001-68; G01N033-53; C07H021-04; C12N009-00; C07K014-435;
C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 47 OF 204 USPTATFULL
AN 2002:98890 USPTATFULL
TI HER -2/neu overexpression abrogates growth inhibitory pathways
IN Slamon, Dennis J., Woodland Hills, CA, UNITED STATES
Wilson, Cindy A., Los Angeles, CA, UNITED STATES
Calzone, Frank J., Westlake Village, CA, UNITED STATES
PA The Regents of the University of California and Angen Inc. (U.S.
corporation)
PI US 2002051785 AI 20020502
AI US 2001-813517 AI 20010320 (9)
PRAI US 2000-190598P 20000320 (60)
DT Utility
FS APPLICATION
LN.CNT 2765
INCL INCLM: 424/145.100
INCL: 514/044.000
NCL INCLM: 424/145.100
NCL: 514/044.000
IC [7]
ICM: A61K039-395
ICS: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 48 OF 204 USPATFULL
AN 2002:92782 USPATFULL
TI Novel macrocyclic magnetic resonance imaging contrast agents
IN Hubin, Timothy J., McPherson, KS, UNITED STATES
PI Meade, Thomas J., Altadena, CA, UNITED STATES
AI US 2002049308 A1 20020425
PRAI US 2001-908436 A1 20010717 (9)
DT Utility 20000717 (60)
FS APPLICATION
LN.CNT 984
INCL INCLM: 534/015.000
INCL INCLS: 540/472.000
NCL NCLM: 534/015.000
IC NCLS: 540/472.000
IC (7)

ICM: C07F005-00

ICS: C07D487-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 49 OF 204 USPATFULL
AN 2002:92295 USPATFULL
TI Methods and products for regulating cell motility
IN Gertler, Frank B., Boston, MA, UNITED STATES
IN Bear, James E., Brighton, MA, UNITED STATES
Loureiro, Joseph J., Cambridge, MA, UNITED STATES
Wenland, Jurgen, Bad Harzburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2002048813 A1 20020425
AI US 2001-823240 A1 20010330 (9)
PRAI US 2000-194564P 20000403 (60)
DT Utility
FS APPLICATION
LN.CNT 3345
INCL INCLM: 435/455.000
INCL INCLS: 424/093.210
NCL NCLM: 435/455.000
IC NCLS: 424/093.210
IC (7)

ICM: A61K048-00

ICS: C12N015-85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 50 OF 204 USPATFULL
AN 2002:78224 USPATFULL
TI Individualized anti-cancer antibodies
IN Young, David S. F., Toronto, CANADA
Takahashi, Miyoko, Toronto, CANADA
PI US 2002041877 A1 20020411
AI US 2000-727361 A1 20001129 (9)
RUI Continuation-in-part of Ser. No. US 1999-415278, filed on 8 Oct 1999, GRANTED, Pat. No. US 6180357
DT Utility
FS APPLICATION
LN.CNT 1220
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC (7)

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:53:01 ON 05 NOV 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
ENTERED AT 10:53:32 ON 05 NOV 2002
9309 S HER2 OR ERB2 OR CERBB2 OR P185
3941 S L1 AND ANTIBODY
503 S L2 AND CHEMOTHERAPEUTIC?
418 DUP REM L3 (85 DUPLICATES REMOVED)
5 S L4 NOT PY=>1996
3941 S L1 AND ANTIBODY
1252 S L6 AND CHEMO?
1178 S L7 AND CANCER
206 S L8 AND COLORECTAL
204 DUP REM L9 (2 DUPLICATES REMOVED)
0 S L10 NOT PY=> 1996

=> d l5 2 all

L5 ANSWER 2 OF 5 CANCERLIT
AN 95611685 CANCERLIT
DN 95611685
TI Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents (Meeting abstract).
AU Basella J; Fan Z; Norton L; Mendelsohn J
CS Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
SO Ann Oncol, (1994) 5 (Suppl 5) A010.
ISSN: 0923-7534.

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Institute for Cell and Developmental Biology
EM 199509
ED Entered STN: 19950906

Last Updated on STN: 19950906
Several lines of evidence suggest that growth factor receptor blockade may enhance the antitumor effects of chemotherapeutic agents. We have produced monoclonal antibodies (MAbs) directed against the epidermal growth factor receptor (EGFR). MAbs 225 (IGI) and 528 (IG2a) are capable of preventing growth of subcutaneous human tumor xenografts in nude mice when treatment is started shortly after tumor cell inoculation, but they are only moderately inhibitory after tumors are well developed. Therefore, we have explored combination treatment with chemotherapeutic agents plus anti-EGFR MAbs. Three drugs have been studied: doxorubicin, paclitaxel (Taxol) and cisplatin. Treatment of well established (greater than 300 mm3) A431 squamous carcinoma xenografts with maximally tolerated doses of doxorubicin (5 mg/kg ip for two successive days) had weak antitumor activity, whereas treatment in combination with either MAbs 528 or 225 at a dose level of 1 mg ip twice a week or higher resulted in eradication of tumors in 40 to 69% of the animals in several independently conducted experiments. Similar results were obtained when the same combination was used in well developed (greater than 200 mm3) MDA-468 breast adenocarcinoma xenografts. In subsequent studies, well developed MDA-468 nude mice xenografts were treated with paclitaxel (10-20 mg/kg weight iv x 2) in combination with MAb 528 2 mg intraperitoneally (ip) twice a week for ten doses. There was striking inhibition of growth compared with animals treated with either paclitaxel or MAb 528 alone. Studies with cisplatin in well established A431 cell xenografts at a maximally tolerated dose of 6 mg/kg x 2 in combination with MAb 225 have also resulted in eradication of xenografts resistant to drug alone. We then analyzed the effects of doxorubicin and paclitaxel in combination with MAb 4D5 directed against the HER2 receptor. BT-474 breast adenocarcinoma cells, which express high levels of HER2, were grown to a mean size of 200 mm3. A dose of 4D5 that resulted in a modest inhibition of growth was chosen for these studies. Treatment with anti-HER2 MAb 4D5 alone (0.3 mg/kg ip twice a week) produced 35% growth

inhibition, paclitaxel alone (20 mg/kg iv) resulted in 35% inhibition and doxorubicin alone (10 mg/kg ip) in 27% inhibition of growth. The combined treatment with paclitaxel plus 4D5 resulted in a major antitumor activity with 93% inhibition of growth, and doxorubicin plus 4D5 gave 70% inhibition. Studies of cisplatin in combination with 4D5 are underway. In all of the studies, MABs did not increase the toxicity of the chemotherapeutic agents in animals as determined by animal survival and weight loss. Clinical trials that build on these results are planned. In summary, anti-EGFR MABs markedly enhance the antitumor effects of the chemotherapeutic agents doxorubicin, paclitaxel and cisplatin. Anti-HER2 MAB also enhances the antitumor effects of doxorubicin and more significantly of paclitaxel. Studies of mechanisms are underway.

RN 15663-27-1 (Cisplatin); 23214-92-8 (Doxorubicin); 33069-62-4 (Paclitaxel)
CN 0 (Antibodies, Monoclonal); 0 (Receptors, Growth Factor)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	100.28	100.49

STN INTERNATIONAL LOGOFF AT 11:20:00 ON 05 NOV 2002